Bio/Pharma Business

Aceragen’s acquisition of Arrevus adds key treatment candidates to its rare disease pipeline.

Following the acquisition, Avantor will have access to Masterflex’s various bioproduction operations.

The research collaboration between Sartorius and Matica Biotechnology will aim to optimize PAT technologies, automation software, and single-use platforms for large-scale viral vector production.

The $691 million deal will see Vertex use Mammoth’s systems to discover and develop in-vivo gene-editing therapies.

Merck’s agreement with the Medicines Patent Pool (MPP) aims to facilitate affordable global access for molnupiravir.

SGS’s new Antwerp, Belgium, clinical research site will house both clinical trial patients and good manufacturing practice drug manufacturing, and its Glasgow, UK, biosafety testing site now has increased testing capacity.

The $19 million contract will expand production capacity of Aptar’s Activ-Film technology, which is used in COVID-19 testing kits.

Aceto will acquire A&C Bio Buffer, including the company’s custom buffer and chemical blend portfolio.

Pharmalex has launched the Biopharma Excellence brand, a new service line that combines the expertise of PharmaLex, ERA Consulting, and Biopharma Excellence.

SGS is investing in a new E&L lab in Navi Mumbai, India, that will provide testing services.

AION Labs will be a first-of-its-kind AI/pharma and computational biology innovation lab aimed at spearheading the adoption of AI technologies and computational science.

This acquisition grants Bionano access to BioDiscovery’s clinical software solution for variant analysis.

Element’s acquisition of Nanosyn is the latest in a series of moves made to strengthen the company’s North American presence.

Pacira’s acquisition grants them access to Flexion’s pain management portfolio.

Supernus will acquire Adamas’ Parkinson's disease treatment portfolio through a $400 million acquisition.

Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.

The collaboration between Sunovion, Sumitomo Dainippon, and Otsuka will focus on four compounds designed to treat neuropsychiatric health conditions.

Certara’s acquisition of Pinnacle 21 grants them access to their compliance validation software.

Takeda will use Selecta Bioscience’s ImmTOR platform to develop gene therapies for lysosomal storage disorders.

Reformulation strategies are useful tools for more than just stretching out the potential return on investment for a product.

DRI’s subsidiary has acquired a royalty interest in Oracea (doxycycline) for $46.4 million.

AstraZeneca’s acquisition of Caelum Biosciences gives them access to CAEL-101, a promising light chain amyloidosis treatment.

Pure Psyence, Pure Extracts and Psyence’s joint venture company, will develop psilocybin-derived treatments.

Merck’s 11.5 billion acquisition of Acceleron gives them access to their lead therapeutic candidate, sotatercept.

KSL Biomedical announced their expansion into Canada with the acquisition of Pulse Scientific and the incorporation of KSL Biomedical Canada.

Boehringer Ingelheim to develop novel cancer therapies by leveraging Abexxa’s breakthrough antibody-based drugs.

Novartis’ acquisition of Arctos Medical could lead to significant advancements in optogenetic therapies for patients with vision loss.

Democrats failed to gain sufficient support to advance long-debated legislation to permit Medicare drug price negotiations.

The joint venture with OSTHUS will expand PharmaLex’s IT consulting and system integration expertise.

AzurRx’s acquisition of First Wave Bio grants them access to their proprietary niclosamide formulations.